Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA supplemental labeling approval for an established antiretroviral combination; regulatory action confirms labeling changes but does not report new clinical trial data or efficacy evidence.